PRESS RELEASE

nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTCQB:NDATF) announces its AI-based depression assessment availability through the largest Canadian electronic medical record ("EMR ") platforms.

Calgary, Alberta – December 12, 2024 - *For Immediate Release* – nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTCQB:NDATF) is pleased to announce the availability of its objective AI-based Comprehensive Mental Condition Probability - Depression ("CMCP-D") module via the three largest Canadian electronic medical records ("EMR") platforms whose offerings feature integration of, or connection to, the OceanMD Forms platform. In Canada alone the largest EMR platforms collectively service more than 60,000 physicians. According to PerplexityAI, 93% of Canadian physicians and over 80% of US office-based physicians use EMR systems to manage patient relations.

James Durward, President, commented, "This availability is a huge step forward toward widespread adoption of our advanced AI-based mental condition prediction system. While the depression assessment is only one of our mental condition assessments, we already have four more objective AI-based assessments in the migration queue. We have also received interest from US-based EMRs regarding native integration of our CMCP system."

The Company further announces that its YMI system is being rebranded and will now be referred to CMCP-5 (Comprehensive Mental Condition Probabilities). Changes to its website are ongoing.

For Further Information, please contact:

Jim Durward, President, CEO/CTO
Email: jimd@ndatalyze.com
nDatalyze Website: https://www.ndatalyze.com

About CMCP-5: CMCP-5 uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. CMCP-5 combines expert-guided machine-learning with a proprietary Reference Database to predict an individual's predisposition toward a variety of common mental conditions, both current and forward in time. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, CMCP-5 aligns societal impact with financial success.